Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

ARNA 1.57 -0.04 (-2.48%)
price chart
Arena Pharmaceuticals Inc. (ARNA) Jumps 9.66% on February 04
Arena Pharmaceuticals Inc. (ARNA) was among the biggest gainers on the Russell 2000 for Thursday February 04 as the stock popped 9.66% to $1.59, representing a gain of $0.14 per share.
Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today
What: Arena Pharmaceuticals (NASDAQ:ARNA) was down as much as 12% today after its marketing partner Eisai released financial results for the first half of its fiscal year.
Needham Reiterates Hold on Arena Pharmaceuticals, Inc. (ARNA) Ahead of Earnings  Smarter Analyst
EPS Forecast Of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) completed the last trading session at 1.61 after touching a high of 1.66 and a low of 1.54.
Today's Hot List: The Walt Disney Company (NYSE:DIS), Arena ...  Stock Transcript
Analyst's Roundup: Arena Pharmaceuticals, Inc.
The shares of Arena Pharmaceuticals, Inc (NASDAQ:ARNA) currently has mean rating of 2.71 while 0 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and 5 recommended as “HOLD”.
How Analysts Feel About Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)?
Shining on Major News: Yahoo! Inc. (NASDAQ:YHOO), Adaptimmune Therapeutics ...  Stock Transcript
Arena Pharmaceuticals, Inc. (ARNA) Earns Hold Rating from Needham & Company LLC
Needham & Company LLC reiterated their hold rating on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in a research note issued to investors on Wednesday, MarketBeat Ratings reports.
Why Arena Pharmaceuticals, Inc. Bulked Up in November
Shares of Arena Pharmaceuticals (NASDAQ:ARNA), a drug developer focused on a variety of ailments including weight control management, vascular diseases, and autoimmune diseases, surged higher by 26% in November, according to data from S&P ...
Biotech Beach: Needham Provides Updates on Gilead Sciences, Inc. (GILD), Arena ...
The biotechnology sector is always volatile, and the recent market sell-off only makes it more so. Consequently, Alan Carr of Needham notes that it is best to focus on “commercial-stage or regulatory-stage companies with substantial cash reserves” at ...
Arena Pharmaceuticals Incorporated (NASDAQ:ARNA) Short Interest Increased By 7.13%
Arena Pharmaceuticals, Inc. is a biopharmaceutical firm focused on discovering, developing and commercializing drugs that target G protein-coupled receptors .
Arena Pharmaceuticals, Inc. – Pipeline Review, Market Share, Stragegy, Size ...
MRS371 “Arena Pharmaceuticals, Inc. Global 2015 Clinical Trials Review, H2” provides an detailed overview of Arena Pharmaceuticals, Inc. scenario. Report includes top line data relating on Arena Pharmaceuticals, Inc. Global clinical trials scenario.
Arena Pharmaceuticals, Inc. (ARNA) Stock Rating Reaffirmed by Needham ...
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)'s stock had its “hold” rating restated by analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday, MarketBeat reports.